Anthem Biosciences Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹594 Cr +8% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
AB

Anthem Biosciences Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Anthem Biosciences Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹418Cr
−22.6% YoY
−31.6% QoQ
Net profit
₹120Cr
−11.8% YoY
−36.8% QoQ
Margin
36%
+1 pp YoY
−8 pp QoQ

What the Q1 FY27 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Price₹882
Market cap₹52.3K Cr
P/E88.2

The short version

Anthem expects overall growth for FY27 to remain intact and consistent with its historical double-digit performance. Q1 FY27 was a soft quarter due to timing shifts in deliveries; business is cyclical with lumpiness expected in quarterly performance.

From Anthem Biosciences Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Moderate growth
  • Anthem expects overall growth for FY27 to remain intact and consistent with its historical double-digit performance.
  • Q1 was a soft quarter with about a 25% YoY decline, but Q2, Q3, and Q4 are expected to see recovery and growth.
  • The business is characterized by quarterly fluctuations (lumpiness) due to customer delivery scheduling.
  • A strong order book with about 60% visibility for the full year provides confidence in achieving growth targets.
  • Growth in specialty ingredients, affected by supply chain pressures, is expected to recover strongly by year-end.
  • New customers, including a recently added Big Pharma client, and increased volumes from existing clients will contribute to growth.

2 more points from Anthem Biosciences Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Anthem Biosciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Unit 4 Expansion:
  • Total capex outlay: Approximately Rs. 1,200 crores for Phase 1.
  • Property size: 30 acres; Phase 1 uses half the area.
  • Capacity addition: 365 kiloliters custom synthesis, 100 kiloliters fermentation, plus food and nutra plant.
  • Timeline: Construction started last year; expected completion by end of FY28.
  • Capex split: Roughly 50% each in FY27 and FY28.
  • Current status: Civil works nearly complete; equipment orders to begin.
  • FY27 Capex:
  • Targeted around Rs. 700 crores, mainly for Unit 4.
  • Post FY28:
  • Capex expected to decline after Unit 4 is commissioned.

2 more points from Anthem Biosciences Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anthem Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • At the start of FY27, Anthem had about 60% of its order book for the full year's delivery already secured.
  • After Q1, despite a muted quarter, the order book was replenished and still stands at approximately 60%.
  • This 60% visibility covers the entire business, including CRDMO, specialty ingredients, and R&D segments.
  • The remaining 40% of the order book typically comes from onboarding new customers or increased volumes from existing clients.
  • Orders are a mix of confirmed and anticipated purchase orders, with rolling forecasts updated every 3 to 6 months.

2 more points from Anthem Biosciences Ltd's call on order book

Create a free account to keep reading this call

Anthem Biosciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Anthem Biosciences Ltd Q1 FY27 results — key figures

Anthem Biosciences Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue418540-22.6%611-31.6%
Operating profit (EBITDA)151191-20.9%267-43.4%
Operating margin36%35%+1 pp44%-8 pp
Profit before tax145186-22%278-47.8%
Net profit (PAT)120136-11.8%190-36.8%
EPS (₹)2.132.42-12%3.38-37%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹594 Cr, net profit ₹211 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anthem Biosciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anthem Biosciences Ltd Q1 FY27 results?

Anthem expects overall growth for FY27 to remain intact and consistent with its historical double-digit performance. Q1 FY27 was a soft quarter due to timing shifts in deliveries; business is cyclical with lumpiness expected in quarterly performance.

What is Anthem Biosciences Ltd share price analysis?

Anthem Biosciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 88.2 with a market cap of ₹52,306 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Anthem Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.